Erratum to: Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

Timothy P. Burkholder · Joshua R. Clayton · Mark E. Rempala · James R. Henry ·
John M. Knobloch · David Mendel · Johnathan A. McLean · Yan Hao ·
David A. Barda · Eileen L. Considine · Mark T. Uhlik · Yuefeng Chen ·
Liandong Ma · Laura J. Bloem · Jacqueline K. Akunda · Denis J. McCann ·
Manuel Sanchez-Felix · David K. Clawson · Michael M. Lahn · James J. Starling

Published online: 20 May 2011
© Springer Science+Business Media, LLC 2011

Erratum to: Invest New Drugs DOI 10.1007/s10637-011-9640-6

The original version of this article unfortunately contained errors. The values found on Table 2 was rounded off in one or two decimal places. Please refer to the next page for the corrected Table 2.

The online version of the original article can be found under at <http://dx.doi.org/10.1007/s10637-011-9640-6>.

T. P. Burkholder (✉) · J. R. Clayton · M. E. Rempala ·
J. R. Henry · J. M. Knobloch · D. Mendel · J. A. McLean ·
Y. Hao · D. A. Barda
Discovery Chemistry Research and Technology,
Eli Lilly and Company,
Indianapolis, IN, USA
e-mail: tpb@lilly.com

E. L. Considine · M. T. Uhlik · Y. Chen · L. Ma ·
J. J. Starling (✉)
Oncology Drug Discovery, Eli Lilly and Company,
Indianapolis, IN, USA
e-mail: Starling_James_J@lilly.com

L. J. Bloem
Lead Generation/Lead Optimization Biology,
Eli Lilly and Company,
Indianapolis, IN, USA

J. K. Akunda
Non-clinical Toxicology, Eli Lilly and Company,
Indianapolis, IN, USA

D. J. McCann
Drug Disposition, Eli Lilly and Company,
Indianapolis, IN, USA

M. Sanchez-Felix
Preformulation, Eli Lilly and Company,
Indianapolis, IN, USA

D. K. Clawson
Structural Biology, Eli Lilly and Company,
Indianapolis, IN, USA

M. M. Lahn
Early Oncology Clinical Investigation, Eli Lilly and Company,
Indianapolis, IN, USA

Table 2 In vitro Inhibition Profile of LY2457546

		Human Kinases	LY2457546	Sunitinib	Sorafenib
Biochemical Inhibition Profile IC ₅₀ (μM)					
		FLT4	0.00156	0.00566	0.0261
		RET	0.00419	0.0485	0.0033
		FLT3	0.0051	0.00659	0.105
		EPHA5	0.0107	8.05	0.531
		EPHB1	0.0214	1.15	0.474
		PDGF-Rb	0.0257	0.0352	0.312
		KDR	0.028	0.0611	0.013
		VEGF-R1	0.0306	0.27	0.241
		EPHA8	0.0335	>20	0.214
		VEGF-R3	0.0341	0.0323	0.0925
		EPHA2	0.0374	9.38	0.276
		EPHB4	0.0398	1.59	0.727
		EPHB2	0.0457	3.13	0.854
		cKIT	0.0738	0.0756	0.966
		EPHA3	0.0998	10.5	1.42
		EPHA4	0.157	11.7	3.26
		EPHA7	0.221	5.38	0.709
		RAF	0.264	>20	0.0195
		EPHA1	0.616	7.08	ND
		p70S6K (percent inhibition at 20 mM)	75.9	92.3	75.6

Cell-Based Target Inhibition Assays IC ₅₀ (μM)					
Cell line	Activator	Phospho end point	LY2457546	Sunitinib	Sorafenib
HUVEC	VEGF	pERK ^{T202Y204}	0.00205	0.0287	ND
MV4-11	constitutively active	pSTAT5 ^{Y694}	0.00039	0.00426	ND
HUVEC	VEGF	pERK ^{pT202Y204} (with BSA)	0.0414	0.0552	0.038
A2780	PDGF	pAKT ^{S473}	0.0588	0.0169	1.33
CHO - Clone113	stable over-expression of TIE2	pTIE2 ^{pY99}	0.166	>10	0.327
HEK293-Clone 25	stable over-expression of EphB4	pEphB4 ^{Y590/Y596}	0.0091	3.013	0.337

Cell-Based Antiproliferation Assay IC ₅₀ (μM)					
			LY2457546	Sunitinib	Sorafenib
MV4-11	constitutively active (FLT3 ITD Mutation D835)		0.000339	0.0196	0.0117